Following initial online publication of the above article, the authors requested the following changes. These have been made to both online and print versions of the article.
The final sentence of the second paragraph of the Introduction has been changed from
Mass spectrometry analysis of iTRAQ-labeled peripheral blood mononuclear cells (PBMC) from CLL patients have identified 39 proteins differentially expressed between CLL samples with and without IGVH mutations; 35 of these were expressed at significantly lower levels in the un-mutated IGVH subgroup [11].
to
Eagle et al. found that mass spectrometry analysis of iTRAQ-labeled peripheral blood mononuclear cells (PBMC) from CLL patients identified 274 proteins that were differentially abundant between CLL samples with and without IGVH mutations; 127 of these proteins were expressed at higher levels in the un-mutated IGVH subgroup [11].
In the Discussion section, the first sentence of the final paragraph has been changed from
To our knowledge, there are no previous reports of the association of transcription intermediary factor 1-beta (TIF1B) with CLL progression.
to
Recently, Eagle et al. [11] reported that transcription intermediary factor 1-beta (TIF1B) was expressed at a higher level in UM-CLL samples, consistent with our results that TIF1B was up-regulated in a group that combined slow progressive and progressive patients from both iTRAQ and SRM analyses.